Positive results from the Phase II study of uTRACE in brain

Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in ...

Related Keywords

Prague , Praha , Hlavníesto , Czech Republic , Denmark , Copenhagen , Køavn , Ulrich Krasilnikoff , Curasightas Curasight , Aleena Azam , University Of Copenhagen , World Molecular Imaging Congress , Primary Gliomas , Prognostic Value , Targeted Radionuclide , Molecular Imaging , Springer Publisher ,